Table 2 Outcome measures by treatment group.

Died in hospital

0 (0%)

2 (5%)

2 (3%)

0.494

Died within 30 days of treatment initiation

0 (0%)

2 (5%)

2 (3%)

0.494

Died within 90 days of treatment initiation

0 (0%)

4 (10%)

4 (5%)

0.116

Admission to ICU

2 (6%)

4 (11%)

6 (8%)

0.675

Admission to discharge (hours) Median (IQR)

69 (48, 116)

121 (69, 179)

94 (56, 169)

0.071

Treatment to discharge (hours) Median (IQR)

48 (24, 98)

98 (46, 165)

73 (26, 144)

0.098

Treatment to clinical stability (hours) Median (IQR)

22 (-4, 90)

49 (18, 137)

41 (10, 98)

0.083

Plasma vitamin C after 24 h, N (%) (median IQR) ^a

29 (81%)

226 (131, 461)

32 (82%)

19 (10, 31)

61(81%)

40 (17, 208)

 < 0.0001

Follow-up

 Completed questionnaire N(%)^b

31 (86%)

32 (86%)

63 (86.3%)

1

 Readmission within 30 days^b

1 (3%)

(day 24)

4 (11%)

(day 1 & 26)

5 (8%)

0.22

 Readmission for CAP^b

1 (2.7%)

1 (2.7%)

2 (2.7%)

1

Further antimicrobial therapy during follow-up^c

7 (19%)

5 (14%)

12 (19.0%)

0.52

 No persisting symptoms^c

8 (22%)

10 (27%)

18 (29%)

0.64

 Cough^c

12 (33%)

10 (27%)

22 (35%)

0.57

 Chest pain^c

3 (8%)

5 (14%)

8 (13%)

0.51

 Shortness of breath^c

14 (39%)

15 (41%)

29 (46%)

0.89

 Returned to normal activities^c

12 (33%)

13 (35%)

25 (40%)

0.88

 Fatigue^c

20 (56%)

14 (38%)

34 (54%)

0.14